Dashboard for the Leading Network of Stock Market and Personal Finance Blogs

Visit Seeking Alpha

Bayer/Onyx Cancer Drug: Possible Additional Indication Looks Promising

Posted on September 27, 2009

After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals (ONXX), is currently approved for liver and kidney cancers.Data from a phase II trial that is studying Nexavar for the additional indication of breast cancer was presented at the ongoing 15th European CanCer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress in Berlin....

Original article link


phase